The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review
暂无分享,去创建一个
Rongling Li | F. Al-Mulla | T. Katsila | M. Abramowicz | Judit Kumuthini | G. Rada | Ghada El-Kamah | M. Thong | Brittany Zick | C. Dandara | H. Monye | M.S. Williams | A. Balasopoulou | Constantina Chalikiopoulou | Laura Findley | E. B. Maceda | Thilina Wanigasekera | Hannah Kennel | Veeramani Marimuthu | M. Williams | Ghada Y El-Kamah | Rongling Li | Marc S. Williams
[1] I. Boutron,et al. Secondary electronic sources demonstrated very good sensitivity for identifying studies evaluating interventions for COVID-19 , 2021, Journal of Clinical Epidemiology.
[2] D. Parums. Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines , 2021, Medical science monitor : international medical journal of experimental and clinical research.
[3] D. Kopans. The wisdom trial is based on faulty reasoning and has major design and execution problems , 2020, Breast Cancer Research and Treatment.
[4] S. Cross,et al. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. , 2020, American journal of human genetics.
[5] I. Boutron,et al. The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic , 2020, Annals of Internal Medicine.
[6] Matthew S. Lebo,et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions , 2020, Nature Communications.
[7] Jingmei Li,et al. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women , 2020, Nature Communications.
[8] G. Guyatt,et al. Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.
[9] Marc S. Williams,et al. Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. , 2020, American journal of human genetics.
[10] Audrey Y. Chu,et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers , 2020, Nature Medicine.
[11] Alicia R. Martin,et al. Clinical use of current polygenic risk scores may exacerbate health disparities , 2019, Nature Genetics.
[12] Kristen S Purrington,et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.
[13] Mary E. Haas,et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.
[14] P. Visscher,et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. , 2017, American journal of human genetics.
[15] R. Green,et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). , 2016, Circulation.
[16] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[17] J. Witte,et al. Comparison of missing data approaches in linkage analysis , 2003, BMC Genetics.
[18] P. Visscher,et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. , 2015, Nature genetics.
[19] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.